ARTICLE | Finance
In BioCentury’s Public Equity Report: Oncology companies tap public markets for more than $1.2B, while Olema draws $250M PIPE for Novartis combo trial
By Paul Bonanos, Director of Biopharma Intelligence
December 7, 2024 12:45 AM UTC
Two biotechs followed clinical updates by tapping public markets for new funding in the wake of the Thanksgiving holiday, raising more than $1.2 billion in total.
The larger offering went to Revolution Medicines Inc. (NASDAQ:RVMD), whose $862.5 million follow-on equaled a January offering by Vaxcyte Inc. (NASDAQ:PCVX) to tie for the year’s second-largest. Revolution initially priced an upsized $750 million offering, exceeding its $600 million target; the fulfillment of the underwriters’ overallotment brought it to the final total…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654405/revolution-janux-prep-for-next-steps-with-follow-on-cash